IKS Health (NSE: IKS) and Certilytics expand agentic AI partnership to automate prior authorisation and close the payer-provider gap

Inventurus Knowledge Solutions Limited (NSE: IKS | BSE: 544309), the Mumbai-listed care enablement company operating as IKS Health, has announced an expanded strategic collaboration with Certilytics, Inc., a Dallas-based artificial intelligence and predictive analytics firm, to deploy agentic AI workflows across prior authorisation processing, member engagement, and consumer price transparency in the United States healthcare market. The partnership integrates Certilytics’ BrainstormAI Studio and CertHLM tools with the IKS Health Agentic Care Enablement Platform, creating a jointly managed system capable of handling more than 70 percent of prior authorisation workflows without human intervention, while retaining clinician oversight on every consequential decision. For IKS Health, the announcement extends a two-year collaboration into operationally deployable territory at a moment when the company is posting quarterly revenue growth of 24 percent year-on-year and actively expanding its AI product suite. The timing also places IKS Health directly in the path of a US healthcare policy environment where prior authorisation reform is attracting congressional scrutiny, making automation at scale both commercially and politically relevant.

How does agentic AI reduce prior authorisation burden for US healthcare providers and payers in 2026?

Prior authorisation has become one of the most expensive and clinically disruptive administrative processes in US healthcare. Physicians and their support staff spend an estimated tens of billions of dollars annually navigating payer-specific rule sets, submitting documentation, and waiting for approvals that directly delay care delivery. The fundamental problem is informational asymmetry: providers operate on clinical logic while payers apply actuarial and contractual logic, and these two systems rarely communicate in real time. The IKS Health and Certilytics collaboration is attempting to solve this at the workflow layer rather than the policy layer, by encoding payer-specific rule sets into AI agents that can match clinical requests against authorisation criteria without manual intermediation.

The stated target of handling more than 70 percent of prior authorisation cases autonomously is an operationally aggressive benchmark. Most revenue cycle management vendors that have published performance figures on automated authorisation fall well short of that threshold, typically citing rates in the 40 to 55 percent range for straight-through processing. If IKS Health and Certilytics can sustain 70 percent autonomous handling at production scale across diverse payer contracts, the reduction in turnaround time and staffing cost for provider clients would be material. The remaining 30 percent of cases, which involve clinical complexity, payer disputes, or ambiguous documentation, would continue to involve the human-in-the-loop model that IKS Health positions as its differentiating quality control layer.

What does Certilytics bring to the IKS Health platform and why does the combination matter for health plans?

Certilytics has been building healthcare-specific agentic AI infrastructure since 2014, which in industry terms makes it a relative veteran in a space where most vendors entered after 2021. The company’s BrainstormAI Studio is a platform designed to allow credentialed healthcare users to construct, test, and deploy AI agents against proprietary data sets under governance frameworks that satisfy HIPAA requirements. Its CertHLM tool is a health language model purpose-trained on healthcare terminology, coding systems, and clinical documentation patterns, as opposed to the general-purpose large language models that most healthcare AI vendors are adapting from consumer or enterprise foundations.

From the perspective of health plans, payers, and plan sponsors, the significance of the collaboration lies in its positioning between the payer and provider rather than exclusively within one constituency. Most revenue cycle management platforms, including IKS Health’s own legacy offering, are built to serve providers in their interactions with payers, which means the analytical intelligence flows in one direction. By incorporating Certilytics’ payer-side analytical capability, the combined platform can in principle model authorisation decisions from both sides of the transaction simultaneously. This bilateral visibility is architecturally distinct from most competitors’ single-sided approaches and could reduce the adversarial friction that characterises prior authorisation disputes between health systems and large commercial insurers.

How does the human-in-the-loop model protect against clinical risk in AI-managed healthcare workflows?

The human-in-the-loop framework that IKS Health describes is not simply a compliance positioning statement. In the context of prior authorisation and clinical outreach, automated errors carry direct patient-safety and liability consequences that are categorically different from errors in, say, a financial reconciliation workflow. An AI agent that misclassifies a prior authorisation case, fails to flag a clinical contraindication during member outreach, or generates an incorrect cost estimate at the point of care can expose both the provider and the payer to regulatory, legal, and reputational risk simultaneously.

IKS Health’s existing workforce of clinical and administrative professionals, which operates across offshore delivery centres and embedded client sites in India and the US, forms the practical substrate of this oversight layer. The company is not deploying AI to replace this workforce but to redirect it toward exception handling and quality assurance, which is a different operational model from vendors that are using AI to reduce headcount. The distinction has commercial implications: IKS Health’s gross margins benefit from offshore labour arbitrage on high-volume routine tasks, while the human oversight layer preserves the professional credibility and client trust that justify premium pricing on complex workflow management. Executing both simultaneously is the operational tightrope that IKS Health must walk as it scales the agentic platform.

What does real-time consumer price transparency mean for patients, employers, and provider revenue at the point of care?

The third use case in the IKS Health and Certilytics collaboration, consumer price transparency, addresses a problem that US healthcare has nominally been working on since the Affordable Care Act era without producing a reliable consumer-facing solution. Most current price transparency tools provide estimates that are accurate only in retrospect, often reflecting billed charges rather than negotiated rates, and delivered days or weeks after the point of care decision is made. The commercial consequence is that patients who receive unexpected bills are significantly more likely to delay future care, dispute charges, or change provider relationships, all of which damage provider revenue integrity.

What IKS Health and Certilytics describe is a system that generates patient-specific financial estimates at the point of care by drawing on real-time payer contract data, patient benefit structure, and clinical coding. Delivering this accurately requires the same bilateral payer-provider data architecture that underpins the prior authorisation use case, which is why the two workflows are more complementary than they might appear at first glance. Employers, who bear an increasing share of self-insured plan costs, are also named as beneficiaries of this functionality. Providing employers with real-time visibility into plan utilisation and member cost exposure could meaningfully improve plan design decisions and population health management programs, which represent an adjacent growth opportunity for both IKS Health and Certilytics beyond the immediate provider market.

How does the IKS Health and Certilytics deal position IKS against competitors in US revenue cycle management and healthcare AI?

The US revenue cycle management and healthcare AI space is experiencing a period of consolidation and capability escalation that is compressing differentiation windows. Large-scale competitors including Optum, Cognizant TriZetto, and nThrive are investing heavily in automation, while newer entrants such as Cohere Health, Infinitus Systems, and Waystar are targeting specific workflow bottlenecks with purpose-built AI. IKS Health’s strategic positioning, as a full-platform operator with offshore delivery capability and now an agentic AI layer, places it in a distinct category from point-solution vendors but exposes it to the implementation risk of trying to do too many things simultaneously.

The Certilytics partnership addresses one of IKS Health’s structural gaps, which is payer-side intelligence. IKS Health’s client base is predominantly provider-facing, comprising health systems, physician groups, and specialty practices. Certilytics brings relationships and analytical models built with and for health plans, which is the other side of the prior authorisation transaction. The combination does not make IKS Health a payer technology company, but it enables IKS Health to credibly market its workflows to provider clients as payer-aware rather than simply payer-compliant. That positioning distinction could influence purchasing decisions at health systems that have grown frustrated with authorisation denial rates under existing revenue cycle management arrangements.

Where does IKS Health stock trade now and does the partnership announcement reflect the company’s current market valuation?

Inventurus Knowledge Solutions Limited shares closed at Rs 1,347.30 on 24 March 2026, the day before this announcement, putting the company at a market capitalisation of approximately Rs 23,116 crore. The stock has declined around 11 percent over the past six months and roughly 9.4 percent over the past twelve months, sitting considerably below its 52-week high of Rs 1,876 while remaining well above its 52-week low of Rs 1,236.80. The trailing price-to-earnings multiple of approximately 34 to 35 times reflects investor recognition of the company’s consistent earnings momentum but also prices in some uncertainty about whether the India-listed parent can fully capture the valuation that a comparable US-listed healthcare technology company might command.

The underlying operational story remains constructive. IKS Health reported Q3 FY2026 revenue of Rs 8,150 million, representing 24 percent year-on-year growth, with EBITDA expanding 40 percent and EBITDA margins improving to 34.6 percent from 30.5 percent a year earlier. Profit after tax grew 41 percent in the same period. Against that backdrop, the stock’s underperformance relative to earnings growth likely reflects broader India IT sector sentiment and the currency exposure inherent in a company that earns primarily in US dollars while reporting in Indian rupees. The Certilytics partnership announcement, in isolation, is unlikely to materially shift near-term trading given that it contains no revenue guidance and no financial terms, but it contributes to the longer-term platform narrative that IKS Health has been building with institutional investors.

What are the execution risks as IKS Health scales agentic AI workflows across prior authorisation and clinical outreach programs?

Partnerships between AI platform vendors and care enablement operators are common in US healthcare. The execution challenge is converting a joint press release into repeatable client deployments at commercially viable unit economics. The IKS Health and Certilytics collaboration faces several identifiable risks at this stage. First, the 70 percent autonomous handling target for prior authorisation assumes access to real-time, structured payer rule sets, and many payers do not publish these in machine-readable format. Building and maintaining a dynamic rule set library across hundreds of payer contracts requires continuous data operations that are expensive and operationally intensive. Second, HIPAA compliance requirements, state-level data privacy regulations, and the emerging federal framework around healthcare AI accountability create a compliance overhead that must be embedded in every agent deployment.

Third, the member engagement use case, which involves proactive clinical outreach to patients to close care gaps, operates in a regulatory environment that is actively evolving. The Federal Trade Commission, the Centers for Medicare and Medicaid Services, and state insurance commissioners have all signalled increased scrutiny of AI-driven patient communication programs in the past eighteen months. Any deployment of Certilytics’ predictive models in patient-facing outreach would need to demonstrate that AI-generated clinical recommendations are supervised and validated at the point of contact, which is exactly the role that the human-in-the-loop layer is meant to play. Whether IKS Health’s existing workforce can scale that oversight function proportionally with the pace of AI deployment is an operational question that the announcement does not resolve.

Key takeaways: What the IKS Health and Certilytics agentic AI expansion means for healthcare investors and operators

• IKS Health and Certilytics are expanding a two-year collaboration into a deployable agentic AI system targeting prior authorisation, member engagement, and point-of-care price transparency, three of the highest-friction cost centres in US healthcare administration.
• The claim that more than 70 percent of prior authorisation workflows will be handled autonomously is among the most aggressive benchmarks published by any healthcare AI vendor and will be closely watched by the revenue cycle management industry if IKS Health discloses client-level performance data.
• Certilytics’ payer-side intelligence, built since 2014 on health plan and employer datasets, fills a structural gap in IKS Health’s predominantly provider-facing platform, giving the combined system bilateral visibility across the authorisation transaction.
• The human-in-the-loop model is not merely a regulatory positioning statement but an operational architecture that redirects IKS Health’s offshore workforce from routine processing to exception management and quality control, preserving margin structure while scaling AI throughput.
• IKS Health reported 24 percent revenue growth and 41 percent PAT growth in Q3 FY2026, making this partnership announcement a capability investment on top of an already-accelerating business rather than a pivot in response to underperformance.
• The stock’s roughly 11 percent six-month decline despite strong earnings likely reflects India IT sector headwinds and dollar-rupee sensitivity rather than fundamental concern about the business, and the current price below the 52-week midpoint may represent a more attractive entry point for long-term institutional investors than the recent high implied.
• Competitors in US revenue cycle management, including Optum, Cognizant TriZetto, and Waystar, will be watching whether IKS Health can sustain the payer-provider bilateral architecture at scale, since replicating that model requires the kind of multi-year payer data relationships that cannot be quickly acquired.
• Consumer price transparency at the point of care, backed by real-time payer contract data, represents an adjacent sales opportunity with self-insured employers who are increasingly seeking real-time visibility into plan utilisation costs.
• Execution risks centre on the accuracy and completeness of real-time payer rule set libraries, the compliance overhead of AI-driven patient outreach, and the capacity of IKS Health’s human oversight workforce to scale proportionally with the agentic platform.
• No financial terms were disclosed, and the announcement carries no near-term revenue guidance, meaning the market impact will likely be assessed when IKS Health provides quarterly operational updates on platform adoption and prior authorisation automation rates.